By Carla Mozee

Biotech firm Gilead Sciences Inc. (GILD) said Friday that it has received a subpoena from the U.S. Department of Health and Human Services requesting documents about the development, marketing and sales of Ranexa.

Ranexa, which is used to treat chronic angina, was developed and originally commercialized by CV Therapeutics, a company acquired by Gilead in April.

-Carla Mozee; 415-439-6400; AskNewswires@dowjones.com